Azelaprag is under clinical development by BioAge Labs and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Azelaprag’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Azelaprag overview
Azelaprag (BGE-105) is under development for the treatment of muscle atrophy, obesity, insulin sensitivity and type 2 diabetes. It is administered through both oral and intravenous routes. The drug candidate acts by targeting apelin APJ receptor and TRPV1 receptor. It was under development for the treatment of heart failure and neuropathic pain.
BioAge Labs overview
BioAge Labs (BioAge) is a clinical-stage biotechnology company. It focuses on the development of new therapies for metabolic diseases by harnessing the biology of human aging. Its main activities include the research and development of potential treatments for obesity and other metabolic diseases, with a focus on the molecular mediators of aging and disease. The company’s pipeline products include Azelaprag, an oral weight loss therapy that is co-administered with incretin drugs; and NLRP3, for metabolic diseases and neuroinflammation. BioAge is headquartered in Richmond, California, the US.
For a complete picture of Azelaprag’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
